MENU
+Compare
NRIX
Stock ticker: NASDAQ
AS OF
Aug 7 closing price
Price
$10.07
Change
-$0.39 (-3.73%)
Capitalization
770.61M

NRIX Nurix Therapeutics Forecast, Technical & Fundamental Analysis

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders... Show more

NRIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for NRIX with price predictions
Aug 07, 2025

NRIX's RSI Oscillator dives oversold zone

The RSI Oscillator for NRIX moved into overbought territory on August 07, 2025. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NRIX advanced for three days, in of 271 cases, the price rose further within the following month. The odds of a continued upward trend are .

NRIX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 06, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on NRIX as a result. In of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for NRIX turned negative on July 15, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at .

NRIX moved below its 50-day moving average on July 31, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for NRIX crossed bearishly below the 50-day moving average on July 30, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRIX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for NRIX entered a downward trend on August 07, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.722) is normal, around the industry mean (18.130). P/E Ratio (0.000) is within average values for comparable stocks, (57.859). NRIX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.470). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (9.083) is also within normal values, averaging (276.117).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. NRIX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
NRIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

NRIX is expected to report earnings to rise 59.54% to -82 cents per share on October 09

Nurix Therapeutics NRIX Stock Earnings Reports
Q3'25
Est.
$-0.83
Q2'25
Beat
by $0.19
Q1'25
Beat
by $0.09
Q4'24
Missed
by $0.07
Q3'24
Est.
$-0.67
The last earnings report on July 09 showed earnings per share of -51 cents, beating the estimate of -71 cents. With 450.63K shares outstanding, the current market capitalization sits at 770.61M.
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which focuses on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
1700 Owens Street
Phone
+1 415 660-5320
Employees
284
Web
http://www.nurixtx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
POSAX8.84N/A
N/A
Principal Global Real Estate Sec A
TRLIX23.56N/A
N/A
Nuveen Large Cap Value R6
HUMDX15.80N/A
N/A
Huber Mid Cap Value Inv
FIEZX13.82N/A
N/A
Fidelity Advisor Total Intl Equity Z
PFSQX25.63N/A
N/A
PGIM Jennison Financial Services R6

NRIX and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NRIX has been closely correlated with KYMR. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if NRIX jumps, then KYMR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NRIX
1D Price
Change %
NRIX100%
-3.63%
KYMR - NRIX
67%
Closely correlated
-4.91%
IDYA - NRIX
60%
Loosely correlated
-5.16%
DNLI - NRIX
59%
Loosely correlated
-0.42%
RNA - NRIX
56%
Loosely correlated
-1.53%
CRNX - NRIX
55%
Loosely correlated
-2.28%
More

Groups containing NRIX

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NRIX
1D Price
Change %
NRIX100%
-3.63%
NRIX
(2 stocks)
81%
Closely correlated
-4.27%